Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) has announced an alliance with ClearNote Health, Inc. to distribute ClearNote's epigenomic 5-hydroxymethylcytosine (5hmC) platform. This partnership aims to expand Personalis' pharmaceutical service offerings and accelerate revenue growth. The platform offers real-time insights into disease-specific pathways, early cancer detection, disease progression monitoring, and understanding of drug resistance mechanisms, contributing to more effective treatments for patients.

Insights

Market Research Analyst

The alliance between Personalis and ClearNote Health signifies a strategic move within the biopharmaceutical sector that is likely to influence competitive dynamics and potentially accelerate revenue growth for Personalis. From a market perspective, this partnership could enhance Personalis's market position by diversifying its service offerings and expanding its technology portfolio. The integration of ClearNote's epigenomic platform with Personalis's existing assays could lead to a more comprehensive suite of diagnostic and monitoring tools for cancer therapies, which may be particularly attractive to biopharma companies looking to invest in advanced genomic technologies.

Moreover, the collaboration could address a growing demand for personalized medicine, as the ability to monitor disease progression and understand drug resistance mechanisms is critical for the development of targeted therapies. As the industry continues to evolve towards precision oncology, partnerships that contribute to this trend are likely to garner significant attention from investors and stakeholders interested in the long-term growth prospects of companies like Personalis.

Medical Research Analyst

The introduction of ClearNote Health's Epigenomics Platform into Personalis's service offerings represents a technological advancement in the field of cancer research and personalized medicine. The 5-hydroxymethylcytosine (5hmC) platform provides a novel method for detecting cancer and monitoring therapeutic response, which could substantially improve the accuracy and efficacy of cancer treatments. The platform's capability to identify changes in gene activation and regulation through cell-free DNA derived from plasma offers a less invasive and potentially more rapid assessment of tumor dynamics compared to traditional tissue biopsies.

From a research standpoint, the application of artificial intelligence to interpret epigenomic data could lead to the discovery of new biomarkers and drug targets, thereby facilitating the development of next-generation cancer therapies. If the platform delivers on its promise, it could significantly reduce the time and cost associated with drug development by providing real-time insights into treatment effectiveness and resistance pathways.

Financial Analyst

Financially, the partnership between Personalis and ClearNote Health has the potential to be accretive to Personalis's earnings, given the high value and demand for innovative cancer detection and monitoring solutions. The ability to offer a differentiated and complementary service could enable Personalis to capture a larger share of the biopharmaceutical development market, which in turn could lead to an increase in its customer base and revenue streams.

However, the successful commercialization and adoption of the epigenomic platform will be key to realizing these financial benefits. Stakeholders should monitor the uptake of the technology in clinical trials and its impact on drug development timelines. Positive outcomes could lead to increased market confidence and investment, while any setbacks in technology performance or integration could pose risks to projected growth.

Personalis to offer ClearNote’s patented Epigenomic Platform to its biopharmaceutical partners

FREMONT, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform.

“We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based epigenomic approach is complementary to our offering as it helps our customers deepen their understanding of a patient’s response to immunotherapies,” said Chris Hall, CEO and President of Personalis. “Commercial partnerships such as this broaden our portfolio and are expected to appeal to a wide range of biopharma customers and accelerate our revenue growth.”

Echoing this sentiment, Dave Mullarkey, CEO of ClearNote Health, remarked, “Partnering with Personalis presents an excellent opportunity to bring our 5hmC technology to the forefront of cancer research. This alliance is a testament to the synergy between our two companies, enabling us to expand our reach and significantly impact the biopharmaceutical industry. Together, we can accelerate the development of personalized therapies and make a real difference in the lives of patients.”

ClearNote Health’s Epigenomics Platform represents a groundbreaking advance in cancer detection, offering real-time insights into disease-specific pathways. By tracking changes in 5hmC levels coupled with artificial intelligence-based analytical methods, the platform can detect cancer earlier, monitor disease progression, understand mechanisms of resistance, and identify promising drug targets and biomarkers. These insights are invaluable for optimizing drug development programs and delivering more effective treatments to patients. The Epigenomics Platform identifies changes in gene activation and gene regulation by labeling specific changes in the 5hmC landscape from plasma-derived cell-free DNA. This rich biological information, as part of clinical trials, enables the monitoring of cancer therapies in real time and contributes to an understanding of drug resistance mechanisms. The partnership marks a pivotal moment in cancer research, leveraging the strengths of both companies to offer unparalleled solutions in the biopharmaceutical industry.

About ClearNote Heath, Inc.

ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health’s first commercially available test is the Avantect™ Pancreatic Cancer Test, which detects the presence of pancreatic cancer signals in patients at high risk of the disease, including those recently diagnosed with Type 2 diabetes. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company’s CLIA- and CAP-accredited laboratory is located in San Diego, Calif. For more information, visit www.clearnotehealth.com or follow the company on X or LinkedIn. To learn more about the Avantect Pancreatic Cancer Test, visit the test website.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Personalis Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of Personalis’ assays or ClearNote Health’s Epigenomics Platform, or the expected benefits of Personalis’ collaboration with ClearNote Health. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the parties’ ability to demonstrate attributes or advantages of ClearNote’s Epigenomics Platform, the success of Personalis’ distribution efforts, or the adoption and use of ClearNote’s Epigenomics Platform by biopharmaceutical customers. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (SEC) on February 23, 2023, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 7, 2023. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130529437/en/

Investors:

Caroline Corner

investors@personalis.com

415-202-5678

Media Contact:

pr@personalis.com

ClearNote Contact:

Dunia Cristan, Health+Commerce

dunia@healthandcommerce.com

Source: Personalis, Inc.

FAQ

What is the ticker symbol for Personalis, Inc.?

The ticker symbol for Personalis, Inc. is PSNL.

What is the alliance between Personalis and ClearNote Health about?

The alliance aims to distribute ClearNote's epigenomic 5-hydroxymethylcytosine (5hmC) platform to expand Personalis' pharmaceutical service offerings.

What is the potential impact of ClearNote's Epigenomics Platform in cancer research?

The platform offers real-time insights into disease-specific pathways, early cancer detection, disease progression monitoring, and understanding of drug resistance mechanisms, contributing to more effective treatments for patients.